Formulari Ubat KKM (FUKKM)

# Generic Name MDC Category Indications Dosage
1621 Valsartan 160 mg and Hydrochlorothiazide 12.5 mg Tablet C09DA03935T1005XX A/KK Treatment of essential hypertension 1 tablet once daily
1622 Valsartan 160 mg Tablet C09CA03000T1002XX A/KK Patients who cannot tolerate ACE inhibitors because of cough, in i) Heart failure ii) Post myocardial infarction i) 40 mg twice daily. Uptitration to 80 mg and 160mg twice daily. Max: 320 mg in divided doses. ii) 20 mg twice daily increased over several weeks to 160mg twice daily if tolerated.
1623 Valsartan 80 mg and Hydrochlorothiazide 12.5 mg Tablet C09DA03935T1001XX A/KK Hypertension in patients who cannot tolerate ACE inhibitors because of cough 1 tablet once daily
1624 Valsartan 80 mg Tablet C09CA03000T1001XX A/KK Patients who cannot tolerate ACE inhibitors because of cough, in i) Heart failure; ii) Post myocardial infarction i) 40 mg twice daily. Uptitration to 80 mg and 160mg twice daily. Max: 320 mg in divided doses. ii) 20 mg twice daily increased over several weeks to 160mg twice daily if tolerated.
1625 Vancomycin HCl 500 mg Injection J01XA01110P4001XX A* Only for the treatment of MRSA and CAPD peritonitis Slow IV infusion, ADULT: 500 mg over at least 60 minutes every 6 hours or 1 g over at least 100 minutes every 12 hours. NEONATE up to 1 week, 15 mg/kg initially, then 10 mg/kg every 12 hours. INFANT 1 - 4 weeks, 15 mg/kg initially then 10 mg/kg every 8 hours. CHILD over 1 month, 10 mg/kg every 6 hours
1626 Varenicline Tartrate 0.5 mg and 1 mg Tablet N07BA03123T1001XX A/KK Smoking cessation treatment 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
1627 Varenicline Tartrate 1 mg Tablet N07BA03123T1002XX A/KK Smoking cessation treatment 0.5 mg once daily for Day 1-3, then 0.5 mg twice daily for Day 4-7, then 1 mg twice daily; duration of treatment is 12 weeks
1628 Varicella Virus Vaccine Live Attenuated Injection J07BK01000P4001XX A* i) Health staff working with children, pregnant women, transplant, cancer and immunocompromised patients who are at high risk of contacting varicella and transmitting it to at risk patients ii) Transplant patients or candidates who are: a) Immunocompetent and not receiving immunosuppressant drugs, do not have graft versus host disease 2 years or more after transplant b) Susceptible to Varicella-Zoster virus at least 3 weeks before grafting iii) Children: a) with impaired humoral immunity b) HIV-infected children more than 12 months of age, in CDC class N1 (asymptomatic) or A1 (mildly symptomatic) with age specific CD4 more than 25% c) with conditions that require systemic steroid therapy less than 2 mg/kg body weight or a total of 20 mg/day of prednisolone or its equivalent. [Those receiving high doses of systemic steroids at 2 mg/kg body weight or more of prednisolone for more than 2 weeks may be vaccinated after steroid therapy has been discontinued for at least three months] iv) Acute lymphoblastic leukemia (ALL) patients with negative history of varicella who:- a) are 12 months to 17 years of age b) have leukemia in remission for at least 12 months c) have a peripheral blood lymphocyte count 700 cells/ mm3 or more. [If platelet count of greater 100,000/mm3 within 24 hours of vaccination are not being submitted to radiotherapy. Chemotherapy should be withheld for seven days before and after immunisation] v) Susceptible subjects in clinical trials who will be submitted for chemotherapy vi) Children and susceptible patients on chronic dialysis ADULT and CHILD 13 years or more: 2 doses of 0.5 ml SC injection separated by 4 - 8 weeks apart. CHILD 12 months - 12 years: 2 doses at least 3 months apart. However, if the second dose is administered a minimum of 28 days after the first dose, it does not need to be repeated.
1629 Vasopressin 20 units/ml Injection H01BA01000P3001XX A i) Pituitary diabetes insipidus ii) Oesophageal variceal bleeding i) 5 - 20 units SC or IM every 4 hours ii) 20 units in 100 - 200 ml 5% dextrose saline over 15 minutes as infusion which may be repeated after at intervals of 1 - 2 hours. Maximum: 4 doses
1630 Vecuronium Bromide 10 mg/10 ml Injection M03AC03320P3001XX A* As an adjunct in anaesthesia to produce skeletal muscle relaxation ADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response
1631 Vecuronium Bromide 4 mg/ml Injection M03AC03320P3002XX A* As an adjunct in anaesthesia to produce skeletal muscle relaxation ADULT & NEONATES > 5 MONTHS Initial: 80-100 mcg/kg as inj. Maintenance: 20-30 mcg/kg, adjust according to response. Alternatively, as continuous infusion at 0.8-1.4 mcg/kg/min after initial IV dose of 40-100 mcg/kg. NEONATE and INFANT up to 4 months: Initially 10 - 20 mcg/kg, then incremental dose to achieve response.
1632 Venlafaxine HCl 150 mg Extended Release Capsule N06AX16110C2002XX A* i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended.
1633 Venlafaxine HCl 75 mg Extended Release Capsule N06AX16110C2001XX A* i) Depression ii) Generalized anxiety disorder iii) Social anxiety disorder (social phobia) iv) Panic disorder i), ii) & iii) ADULT: 75 mg once daily. May increase dose by 75 mg/day every 4 days to a maximum dose of 225 mg/day, (severe depression: max: 375mg/day) iv) 37.5 mg/day for the first 4-7 days after which the dose should be increased to 75 mg once daily. CHILD and ADOLESCENT under 18 years not recommended
1634 Verapamil HCl 2.5 mg/ml Injection C08DA01110P3001XX A/KK Supraventricular tachycardia Initially 5-10mg given by slow IV over at least 2 minutes. The dose can be repeated 10mg 30 minutes after the first dose if the initial response is not adequate.
1635 Verapamil HCl 40 mg Tablet C08DA01110T1001XX B i) Supraventricular tachyarrhythmias (SVT) prophylaxis ii) angina ADULT: 40 - 80 mg 3-4 times daily. In oral long term therapy, max: 480 mg daily
1636 Vildagliptin 50 mg and Metformin HCl 1000 mg Tablet A10BD08926T1002XX A/KK FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
1637 Vildagliptin 50 mg and Metformin HCl 500 mg Tablet A10BD08926T1003XX A/KK FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. 50/500mg or 50/850mg or 50/1000mg twice daily. Maximum daily dose is 100mg vildagliptin and 2000mg metformin.
1638 Vildagliptin 50 mg and Metformin HCl 850 mg Tablet A10BD08926T1001XX A/KK FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. - Treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets. 50 mg/850 mg or 50 mg/1000 mg twice daily. Maximum daily dose is 100 mg vildagliptin plus 2000 mg metformin hydrochloride.
1639 Vildagliptin 50 mg Tablet A10BH02000T1001XX A/KK FUKKM restriction: As add-on therapy for patient who failed therapy and/or contraindicated/unable to tolerate metformin and/or sulphonylurea. i) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of metformin monotherapy and high risk of hypoglycaemia. ii) As second line therapy in type 2 diabetes patients inadequately controlled on maximal tolerated dose of sulphonylurea and intolerant/contraindicated for metformin therapy. iii) As third line therapy in type 2 diabetes patients inadequately controlled with dual OAD combination therapy with sulphonylurea and metformin iv) As a monotherapy in type 2 diabetes mellitus patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. v) An adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As a dual therapy in combination with insulin in patients with insufficient glycaemic control. Insulin dose and regimen should be optimized before addition of vildagliptin. ADULT over 18 years: 50mg bd when combine with metformin, 50 mg od when combine with sulphonylurea
1640 Vinblastine Sulphate 10 mg Injection L01CA01183P3002XX A Hodgkin's disease, choriocarcinoma resistant to other chemotherapeutic agents, non-small cell lung cancer, Langerhans cell histiocytosis Adult: Initially, 3.7 mg/m2, increase dose weekly based on WBC counts in increments of about 1.8 mg/m2 until leukocyte count decreases to about 3000/mm3, or maximum weekly dose of 18.5 mg/m2 reached. Usual dose: 5.5-7.4 mg/m2 per week. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3. Child: Initial 2.5 mg/m2 of BSA, increased dose at weekly intervals in increments of about 1.25 mg/m2 until leukocyte count decreases to about 3000/ mm3, or maximum weekly dose of 12.5 mg/m2 reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm3, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance. Do not administer next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm3.
1641 Vincristine Sulphate 1 mg/ml Injection L01CA02183P3001XX A i) Solid tumours ii) Gestational trophoblastic disease iii) Non-Hodgkin's lymphoma iv) Multiple myeloma v) Acute lymphoblastic leukemia i) ADULT: 1.4 mg/m2 weekly (maximum 2 mg weekly) ii) Refer to protocol iii) 1.4 mg/m2 weekly (maximum 2 mg weekly) iv) 0.4 mg/m2 IV continuous infusion on days 1 - 4 v) Refer to protocol. CHILD: 1 mg/m2 to 2 mg/m2 weekly according to protocol (0.05 mg/kg for infants less than 10kg)
1642 Vinorelbine 10 mg Injection L01CA04000P4001XX A* i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast cancer i) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion
1643 Vinorelbine 50 mg Injection L01CA04000P4002XX A* i) First line treatment in non-small cell lung cancer in combination with cisplatin/ifosfomide ii) Metastatic breast cancer i) Single agent: Adult 30mg/m2 IV administered over 6-10 minutes once weekly Combination with cisplatin : 30mg/m2 IV administered over 6-10mintes once weekly combination with cisplatin IV on days and 29 and then every 6 weeks or Vinolrebine administered at a dose of 25mg/m2 IV weekly in combination with cisplatin given every 4 weeks at a dose of 100mg/m2 ii) 25 - 30 mg/m2 diluted in saline solution, infused over 6 - 10 minutes, administered weekly or vinolrebine maybe given as an 8mg/m2 IV BOLUS followed by 8mg/m2 as a 96-hour intravenous infusion.
1644 Vitamin A & D (Cod Liver Oil) A11CB00901L5001XX C Prevention of ricketts Not more than 10 ml daily, allowance being made for Vitamin D obtained from other sources
1645 Vitamin A & D Concentrate 25,000 units/0.6ml Liquid A11CB00901L5002XX B Prevention of ricketts 0.06 - 0.6ml (2,500-25,000 IU of Vitamin A and 250-2,500 IU of D) daily, allowance being made for A and D obtained from other sources
1646 Vitamin A 50,000 IU Capsule A11CA01000C1001XX C Children with measles malnutrition and serious infections. Category C can use this drug for Orang Asli and in Sabah i) 0-5 months, 50,000 IU ii) 6-11 months, 100,000 IU iii) 1-5 years, 200,000 IU. Frequency twice daily
1647 Vitamin B Complex 10 ml Injection A11EX00901P3001XX B Prophylaxis and treatment of vitamin B deficiency 1-2 ml daily by IM
1648 Vitamin B Complex Tablet A11EA00901T1001XX C+ Prophylaxis and treatment of vitamin B deficiency 1-2 tablets daily
1649 Vitamin B1, B6, B12 Injection A11DB00901P3001XX B For deficiency or raised requirement of Vitamin B1, B6, B12 Mild cases: 1 ampoule given by IM 2-3 times weekly. Severe cases: 1 ampoule daily
1650 Vitamin B1, B6, B12 Tablet A11DB00901T1001XX B For deficiency or raised requirement of Vitamin B1, B6, B12 1 - 3 tablets 3 times daily swallowed unchewed.

Halaman-halaman